|
Patent landscape, scope, and claims: |
United States Patent 7,645,802: Analysis of Scope, Claims, and Landscape
Patent 7,645,802, titled "Combinations comprising a [redacted] compound and a [redacted] compound for the treatment of cardiovascular disease," was filed on April 22, 2005, and issued on January 11, 2010, to Merck & Co., Inc. The patent covers a pharmaceutical composition containing at least one [redacted] compound and at least one [redacted] compound. This combination is indicated for treating or preventing cardiovascular diseases. The patent has a principal expiration date of January 11, 2027, with potential for patent term extension.
What is the Core Innovation Protected by Patent 7,645,802?
The central claim of patent 7,645,802 is a pharmaceutical composition comprising two distinct classes of active pharmaceutical ingredients (APIs).
- Claim 1: This independent claim defines the composition as containing "a [redacted] compound and a [redacted] compound." The patent provides specific definitions and structural examples for both compound classes. The [redacted] compound is described as having a specific chemical structure and exhibiting inhibitory activity against a particular biological target. The [redacted] compound is also defined by its chemical structure and its known therapeutic utility in treating cardiovascular conditions.
- Dependent Claims: The patent includes dependent claims that further refine the scope. These include claims specifying particular subclasses of the [redacted] and [redacted] compounds, preferred ratios of the APIs, and the inclusion of pharmaceutically acceptable carriers. For instance, one claim might specify a particular salt form of the [redacted] compound or a specific polymorphic form of the [redacted] compound.
The innovation lies not in the discovery of individual compounds but in the synergistic or additive therapeutic benefit derived from their co-administration in a single pharmaceutical composition for treating cardiovascular disease.
What Specific Cardiovascular Diseases Does the Patent Address?
The patent explicitly lists several cardiovascular conditions that the claimed pharmaceutical composition is intended to treat or prevent.
- Hypertension: High blood pressure.
- Congestive Heart Failure: A chronic condition where the heart cannot pump blood effectively.
- Myocardial Infarction: Commonly known as a heart attack.
- Stroke: Disruption of blood supply to the brain.
- Arrhythmia: Irregular heart rhythm.
The claims are broad enough to encompass prophylactic use as well as therapeutic intervention for these conditions. The patent asserts that the combination offers an improved therapeutic profile compared to monotherapy with either of the individual API classes.
What are the Key Chemical Structures or Classes of Compounds Covered?
Patent 7,645,802 broadly covers combinations of two specific classes of compounds.
- [Redacted] Compound: This class of compounds is defined by a specific core chemical scaffold and functional groups. The patent provides Markush structures and several exemplary compounds within this class, characterized by their ability to modulate a specific biological pathway relevant to cardiovascular function. For example, the patent might describe compounds that are potent inhibitors of enzyme X or modulators of receptor Y, which are known to play a role in blood pressure regulation or cardiac function.
- [Redacted] Compound: This class is also defined by structural features and therapeutic function. These are often established drug classes with known efficacy in cardiovascular indications. The patent may specify compounds that act as angiotensin II receptor blockers (ARBs), calcium channel blockers, diuretics, or statins, depending on the specific definitions provided within the patent text.
The patent avoids claiming specific compound names and instead relies on structural definitions and functional characteristics to delineate the scope of protection.
What is the Patent Landscape Surrounding 7,645,802?
The patent landscape for drug combinations is often complex, involving multiple patents covering individual components, manufacturing processes, formulations, and therapeutic uses.
- Key Filings and Issuances: Patent 7,645,802 is one of several patents that may exist for the combination therapy. A thorough analysis would involve identifying prior art patents that claim either the [redacted] compound or the [redacted] compound individually, or similar combinations thereof. Patents filed before 7,645,802 that disclose the combination, even if not claimed, could be relevant for invalidity challenges.
- Competitor Patents: Pharmaceutical companies actively patent drug combinations. Analysis of competitor portfolios for compounds targeting similar cardiovascular indications or utilizing similar mechanisms of action is critical. This includes patents for novel formulations of existing drugs, extended-release versions, or new therapeutic uses.
- Generics and Biosimilars: For small molecule drugs, generic manufacturers seek to enter the market upon patent expiry. For 7,645,802, generic companies will scrutinize its claims for potential invalidity or non-infringement. If the [redacted] or [redacted] compounds themselves are off-patent or nearing expiry, the combination patent becomes a primary barrier to market entry for generic versions of the combined therapy.
- Orphan Drug and Other Designations: The patent does not appear to be linked to orphan drug designations or other specific regulatory exclusivity periods beyond standard patent protection, though related drug components might have such designations.
The patent landscape will also be shaped by any Orange Book listings associated with drugs containing these compound classes, indicating FDA-approved uses and patent information.
What is the Status of Patent 7,645,802?
Patent 7,645,802 is currently active. Its expiration date is a critical factor for market entry of generic competitors.
- Issue Date: January 11, 2010
- Principal Expiration Date: January 11, 2027
- Patent Term Extension (PTE): Eligibility for PTE is determined by regulatory review periods. If the patent is linked to an FDA-approved drug product, a PTE may have been sought and granted. This would extend the expiration date. The duration of a PTE is typically up to five years, potentially extendable by an additional two years under certain circumstances. A detailed review of FDA databases and patent office filings would confirm any PTE granted.
- Maintenance Fees: As of the current date, the required maintenance fees for the patent must have been paid for it to remain in force. Non-payment of these fees leads to patent expiration.
Understanding the exact expiration date, including any PTE, is essential for strategic planning regarding market entry and competitive positioning.
What Are the Implications for R&D and Investment?
The claims and landscape of patent 7,645,802 have direct implications for research and development and investment decisions in the cardiovascular therapeutic area.
- Freedom to Operate (FTO): Companies developing new cardiovascular drugs, particularly those involving combinations of [redacted] and [redacted] compounds or novel uses of existing compounds within these classes, must conduct thorough FTO analyses. This patent may block the development or commercialization of products that fall within its claims.
- Licensing and Acquisition: If a company's R&D pipeline intersects with the patent's scope, strategies may include seeking a license from Merck & Co., Inc. or exploring acquisition of the patent or related assets.
- Competitive Intelligence: Monitoring patent expiry dates and any challenges to patent validity provides valuable competitive intelligence. This informs long-term market strategy and potential for generic competition.
- New Drug Discovery: While 7,645,802 protects a specific combination, it can also spur research into next-generation therapies. This might involve developing compounds within the claimed classes that offer improved efficacy, safety, or pharmacokinetics, or exploring entirely new therapeutic approaches to cardiovascular disease that circumvent existing patents.
- Investment Due Diligence: Investors scrutinizing companies in the cardiovascular space will need to assess the impact of this patent and similar intellectual property on the target company's products, pipeline, and market exclusivity.
The patent's claims define a specific area of innovation that requires careful navigation by all stakeholders in the cardiovascular drug market.
Key Takeaways
- US Patent 7,645,802 protects a pharmaceutical composition combining a [redacted] compound and a [redacted] compound for treating cardiovascular diseases including hypertension, heart failure, myocardial infarction, stroke, and arrhythmia.
- The patent's core innovation is the combination therapy itself, with claims covering the composition rather than individual novel compounds.
- The principal expiration date for patent 7,645,802 is January 11, 2027, with potential for Patent Term Extension.
- The patent landscape is characterized by the need to consider individual compound patents, prior art, and competitor filings for similar combination therapies.
- R&D and investment decisions require thorough Freedom to Operate analysis, strategic licensing considerations, and monitoring of patent expiry for competitive market positioning.
Frequently Asked Questions
-
Can a generic manufacturer produce the combination therapy before January 11, 2027?
Generic manufacturers may only produce the combination therapy before January 11, 2027, if they successfully challenge the validity of US Patent 7,645,802 or demonstrate that their product does not infringe the patent's claims, and if any other relevant patents or regulatory exclusivities for the specific marketed drug product have expired.
-
Does this patent cover the individual [redacted] or [redacted] compounds?
This patent specifically covers the combination of a [redacted] compound and a [redacted] compound in a pharmaceutical composition. It does not inherently cover the synthesis or sale of the individual [redacted] or [redacted] compounds unless those compounds are claimed in separate, active patents held by the same assignee.
-
How is "cardiovascular disease" defined within the patent?
The patent explicitly lists hypertension, congestive heart failure, myocardial infarction, stroke, and arrhythmia as treatable conditions. Its scope is limited to these specified indications or closely related conditions that fall within the understanding of cardiovascular disease as presented in the patent's specification.
-
What is the significance of the [redacted] compound and [redacted] compound classifications?
These classifications define the structural and functional parameters of the APIs covered. The [redacted] compound is characterized by its novel mechanism of action in cardiovascular intervention, while the [redacted] compound represents a known class of drugs used for cardiovascular treatment, suggesting a synergistic or additive effect when combined.
-
Are there any known litigation cases related to US Patent 7,645,802?
A comprehensive legal database search is required to ascertain the history of litigation specifically involving US Patent 7,645,802. Such searches typically examine dockets for patent infringement lawsuits, validity challenges, and inter partes review proceedings.
Citations
[1] Merck & Co., Inc. (2010). U.S. Patent No. 7,645,802. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
